Resources
News

James Roosevelt Jr., Longtime Health Care Executive & Prominent Attorney, Joins Verrill Dana

January 17, 2017 Press Releases

(January 17, 2017) – Verrill Dana is pleased to announce that James Roosevelt Jr. has joined the firm's Boston office.

One of the longest serving health care executives in the state, Roosevelt has reentered private practice after more than 10 years as the President and Chief Executive Officer of Tufts Health Plan. Under his leadership, Tufts Health Plan's membership grew significantly, expanded its geographic reach and increased revenues.

Roosevelt brings experience from both the provider and payer perspectives, having chaired the Massachusetts Hospital Association, the Massachusetts Association of Health Plans and America's Health Insurance Plans, and served on the board of the American Hospital Association. He is also a past president of the American Health Lawyers Association.

In 2016, Roosevelt was a distinguished Visiting Fellow at Harvard's Institute of Politics at the John F. Kennedy School of Government. He chairs the Policy and Regulatory Committee of America's Health Insurance Plans. He is a member of the board of directors of Alere Inc. and serves as the chair of its Compensation Committee and member of its Nominating and Governance Committees. He is also a member of the Executive Committee and co-chairs the Rules and By-laws Committee of the Democratic National Committee, as well as volunteering as chief legal counsel of the Massachusetts Democratic Party. In 2008, President-elect Barack Obama appointed Roosevelt to his transition team to co-chair a review of the Social Security Administration. Prior to his role at Tufts Health Plan, he was a partner at a major Boston-based law firm. Roosevelt earned his undergraduate degree from Harvard College and his J.D. from Harvard Law School. He also completed the Advanced Management Program at the Harvard Business School.

"Jim's experience and leadership in the health care industry make him an invaluable addition to our Group and to the firm," said Jeffrey Heidt, Chair of Verrill Dana's Health Care Group. "The health care sector is constantly evolving and shifting, sometimes tumultuously, and Jim has the legal judgment, practical acumen, and big-picture understanding to help our clients make smart adjustments."

Last year, Verrill Dana's Health Care Group welcomed three new attorneys and, with the addition of Roosevelt, has grown 25% since 2015. The Group was also recognized last year by the American Bar Association's Health Law Section, Acquisition International, U.S. News & World Report, and the Chambers & Partners Guide.

Firm Highlights

News

38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...

News

Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...

Publication/Podcast

News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...

Publication/Podcast

FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...

Publication/Podcast

EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...

News

Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

Publication/Podcast

FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.